Research graph
References from Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registry. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
Unresolved reference
External reference
Extensive-stage small-cell lung cancer: first-line and second-line treatment options
10.1200/jco.21.01881 · 2022 · External reference
Lung Cancer in Austria
10.1016/j.jtho.2020.10.158 · 2021 · External reference
Advancements in small cell lung cancer
10.1016/j.semcancer.2023.05.008 · 2023 · External reference
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
10.1038/s41571-024-00914-x · 2024 · External reference
Small cell lung cancer: a review
10.1001/jama.2025.0560 · 2025 · External reference
Current standards for clinical management of small cell lung cancer
10.21037/tlcr.2018.01.16 · 2018 · External reference
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
10.1016/s0140-6736(19)32222-6 · 2019 · External reference
First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
10.1056/nejmoa1809064 · 2018 · External reference
Pembrolizumab or Placebo Plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study
10.1200/jco.20.00793 · 2020 · External reference
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
10.1200/jco.2006.06.5821 · 2006 · External reference
10.1007/s00508-024-02351-3
10.1007/s00508-024-02351-3 · External reference
The 2021 WHO classification of lung tumors: impact of advances since 2015
10.1016/j.jtho.2021.11.003 · 2022 · External reference
The international association for the study of lung cancer staging project for lung cancer: proposals for the revision of the M descriptors in the forthcoming ninth edition of the TNM classification for lung cancer
10.1016/j.jtho.2024.01.019 · 2024 · External reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
Unresolved reference
External reference
Clinical impact of EGFR mutation subtypes on treatment outcomes in advanced non-small cell lung cancer: an austrian real-world study
10.3390/cancers18020278 · 2026 · External reference
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
10.1177/17588359221103206 · 2022 · External reference
Neoadjuvant therapy in early-stage non-small cell lung cancer: a real-world analysis
10.1016/j.lungcan.2024.107997 · 2024 · External reference
The efficacy of first-line pembrolizumab monotherapy in patients with metastatic NSCLC Aged ≥70 years with high PD-L1 (TPS ≥ 50%) expression: a multicenter real-world study
10.3390/cancers17132190 · 2025 · External reference
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
10.1056/nejmoa1809064 · 2018 · External reference
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
10.1016/s0140-6736(19)32222-6 · 2019 · External reference
The Italian Mauris phase IIIb trial of atezolizumab plus carboplatin and etoposide for patients with newly diagnosed extensive-stage small cell lung cancer: 3-year end-of-study results
10.1016/j.cllc.2025.07.003 · 2025 · External reference
10.1016/j.annonc.2022.07.1626
10.1016/j.annonc.2022.07.1626 · 2022 · External reference
Unresolved reference
External reference
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
10.1016/s0140-6736(25)01011-6 · 2025 · External reference
Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
10.57264/cer-2022-0098 · 2023 · External reference
Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: a large French multicenter study
10.1016/j.lungcan.2024.107887 · 2024 · External reference
Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme
10.1111/imj.16348 · 2024 · External reference
P1.13B.01 lurbinectedin vs. platinum rechallenge in extensive stage small cell lung cancer after platinum doublet, a multicenter retrospective study
10.1016/j.jtho.2024.09.1412 · 2024 · External reference
Brief report: real-world outcomes of lurbinectedin in veterans with small cell lung cancer
10.1016/j.cllc.2026.02.007 · 2026 · External reference
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
10.1016/s1470-2045(20)30068-1 · 2020 · External reference
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – a decision-making analysis amongst European lung cancer experts
10.1016/j.lungcan.2020.03.024 · 2020 · External reference
Unresolved reference
External reference
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
10.1200/jco.1999.17.2.658 · 1999 · External reference
10.1016/j.jtocrr.2026.100959
10.1016/j.jtocrr.2026.100959 · External reference
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
10.1016/s1470-2045(20)30461-7 · 2020 · External reference
Tarlatamab in small-cell lung cancer after platinum-based chemotherapy
10.1056/nejmoa2502099 · 2025 · External reference
Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer
10.1016/j.lungcan.2026.109390 · 2026 · External reference
Optimizing tarlatamab delivery in small cell and neuroendocrine lung cancer: real-world insights into step-up dosing and prophylactic tocilizumab use
10.1016/j.cllc.2025.11.018 · 2026 · External reference
Real-world outcomes of tarlatamab in small cell lung cancer, including patients with untreated brain metastases
10.1016/j.cllc.2025.03.006 · 2025 · External reference
Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer
10.1200/jco.2025.43.16_suppl.8088 · 2025 · External reference
Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice
10.1016/j.ejca.2026.116686 · 2026 · External reference
Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer
2025 · External reference
